Breast implant guidance
This article was originally published in The Gray Sheet
Executive Summary
Comments on FDA's Jan. 8 draft guidance on saline, silicone and "alternative" breast implants are due to the agency by April 12. The guidance was released after FDA issued a "not approvable" letter for Inamed's silicone breast implant premarket application (1"The Gray Sheet" Jan. 12, 2003, p. 3)...
You may also be interested in...
Breast Implant PMA Timeframes Tested By Inamed “Not-Approvable” Letter
Firms seeking premarket approval for silicone breast implants should conduct tests designed to more closely predict rupture and gel bleed under real-world conditions, according to new FDA draft guidelines
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.